JP2020073504A5 - - Google Patents

Download PDF

Info

Publication number
JP2020073504A5
JP2020073504A5 JP2019229640A JP2019229640A JP2020073504A5 JP 2020073504 A5 JP2020073504 A5 JP 2020073504A5 JP 2019229640 A JP2019229640 A JP 2019229640A JP 2019229640 A JP2019229640 A JP 2019229640A JP 2020073504 A5 JP2020073504 A5 JP 2020073504A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antibody
seq
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019229640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020073504A (ja
Filing date
Publication date
Priority claimed from EP13178958.8A external-priority patent/EP2832747A1/en
Application filed filed Critical
Publication of JP2020073504A publication Critical patent/JP2020073504A/ja
Publication of JP2020073504A5 publication Critical patent/JP2020073504A5/ja
Priority to JP2022019186A priority Critical patent/JP7492981B2/ja
Pending legal-status Critical Current

Links

JP2019229640A 2013-08-01 2019-12-19 抗garpタンパク質及びその使用 Pending JP2020073504A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022019186A JP7492981B2 (ja) 2013-08-01 2022-02-10 抗garpタンパク質及びその使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361861008P 2013-08-01 2013-08-01
US61/861,008 2013-08-01
EP13178958.8A EP2832747A1 (en) 2013-08-01 2013-08-01 Anti-GARP protein and uses thereof
EP13178958.8 2013-08-01
EP14167425.9 2014-05-07
EP14167425 2014-05-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016530550A Division JP2016529892A (ja) 2013-08-01 2014-08-01 抗garpタンパク質及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022019186A Division JP7492981B2 (ja) 2013-08-01 2022-02-10 抗garpタンパク質及びその使用

Publications (2)

Publication Number Publication Date
JP2020073504A JP2020073504A (ja) 2020-05-14
JP2020073504A5 true JP2020073504A5 (https=) 2020-10-01

Family

ID=52431038

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016530550A Withdrawn JP2016529892A (ja) 2013-08-01 2014-08-01 抗garpタンパク質及びその使用
JP2019229640A Pending JP2020073504A (ja) 2013-08-01 2019-12-19 抗garpタンパク質及びその使用
JP2022019186A Active JP7492981B2 (ja) 2013-08-01 2022-02-10 抗garpタンパク質及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016530550A Withdrawn JP2016529892A (ja) 2013-08-01 2014-08-01 抗garpタンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022019186A Active JP7492981B2 (ja) 2013-08-01 2022-02-10 抗garpタンパク質及びその使用

Country Status (16)

Country Link
US (5) US10000572B2 (https=)
EP (2) EP3027650B1 (https=)
JP (3) JP2016529892A (https=)
KR (2) KR20220025174A (https=)
CN (2) CN113583128A (https=)
AU (3) AU2014298373B2 (https=)
BR (1) BR112016002199B8 (https=)
CA (1) CA2919765C (https=)
EA (1) EA035550B1 (https=)
ES (1) ES2860952T3 (https=)
IL (2) IL243899B (https=)
MX (2) MX377091B (https=)
NZ (1) NZ717476A (https=)
SG (2) SG11201600741SA (https=)
WO (1) WO2015015003A1 (https=)
ZA (1) ZA201601085B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
JP2018529642A (ja) * 2015-07-22 2018-10-11 ホスピタル サント ジョアン デ デューHospital Sant Joan De Deu Casrを発現する癌(例えば神経芽腫)のための免疫療法
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
CN114470194A (zh) * 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス,インク. 単一ドメイン血清アルブミン結合タンパク質
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20190292254A1 (en) * 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
CN110520524A (zh) * 2017-04-14 2019-11-29 综合医院公司 靶向肿瘤微环境的嵌合抗原受体t细胞
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
US20210038646A1 (en) * 2018-02-12 2021-02-11 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
WO2020079595A1 (en) * 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
EP4049675A4 (en) * 2019-10-25 2023-11-22 Daiichi Sankyo Company, Limited COMBINATION OF ANTI-GARP ANTIBODIES AND IMMUNE REGULATOR
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
JP7511377B2 (ja) * 2020-04-16 2024-07-05 デンカ株式会社 アデノウイルスの免疫測定方法及び免疫測定器具
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性rna
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CA3208624A1 (en) * 2021-01-18 2022-07-21 Shanghai Jemincare Pharmaceutical Co., Ltd. Garp protein antibody and application thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるcd40およびcd137に対する多重特異性結合剤
AU2022363845A1 (en) * 2021-10-11 2024-05-30 Musc Foundation For Research Development Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル T細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのgarp
US20240042020A1 (en) 2022-07-29 2024-02-08 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4720122A1 (en) * 2023-06-05 2026-04-08 Pure Biologics Spólka Akcyjna Anti-garp antibodies and methods of use
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
EP3178496A1 (en) * 2007-08-24 2017-06-14 Keio University Fstl1 suppressor for use in the treatment of tumours
AU2008317331B2 (en) * 2007-10-25 2013-08-29 The Scripps Research Institute Antibody-mediated disruption of quorum sensing in bacteria
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
DK3153526T3 (da) * 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
IN2015DN00140A (https=) 2012-08-31 2015-06-12 Argen X Bv
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses

Similar Documents

Publication Publication Date Title
JP2020073504A5 (https=)
JP7607498B2 (ja) 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
TWI805121B (zh) 抗SIRPα抗體及其用途
AU2017203523B2 (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
JP6728053B2 (ja) 抗mcam抗体及び関連する使用方法
JP2019116474A5 (https=)
JP2019513018A5 (https=)
JP2022104966A (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
JP2013502913A5 (https=)
JPWO2020114480A5 (https=)
EP3092252B1 (en) Antibody targeting cell surface deposited complement protein c3d and use thereof
JP2021512604A5 (https=)
JP2021511387A5 (https=)
JP2021529524A5 (https=)
CN114829405B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
JP2021523906A5 (https=)
JP2023103439A (ja) 固形腫瘍の治療に有益な抗体およびその抗体-薬物コンジュゲート並びにこれらを含む抗がん剤
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
KR20250029205A (ko) 종양 항원에 대한 인간화 항체 또는 이의 기능적 단편
GB2524553A (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer cachexia
KR20250012612A (ko) 고형 종양을 치료하는 방법
CN119095878A (zh) 特异性结合muc-1的抗体及其用途
RU2822496C1 (ru) АНТИТЕЛО К SIRPα И ЕГО ПРИМЕНЕНИЕ
JPWO2021141907A5 (https=)
CN118159559A (zh) 一种抗b7-h4抗体及其制备方法和应用